Which GLP-1 is right for you? The honest decision guide

Check the formulary before falling in love with a molecule: plans routinely prefer one product, exclude weight-management drugs entirely, or gate everything behind prior authorization. The covered option at slightly lower average efficacy usually beats the uncovered ideal, because the uncovered ideal gets abandoned at month four.

No coverage is not no options: manufacturer self-pay channels price authentic product well below list, and generic liraglutide undercuts everything. The cost post maps the levers in detail; run it before deciding anything on sticker prices.

Averages rank cleanly: tirzepatide around 20%, semaglutide 2.4 around 15%, oral semaglutide below its injectable sibling, liraglutide around 8%. If your health picture calls for maximum loss (severe obesity, weight-responsive conditions stacking up), the averages argue for starting strong, coverage permitting.

If your target is more modest (say 10 to 15% with maintenance), several options plausibly get you there, and the decision tilts toward whichever is cheapest and easiest to sustain. Remember the spread: individuals out-perform and under-perform every mean, and your response is discoverable only by trying.

A weekly shot is one decision a week, needle included; most people stop noticing the needle within a month. The daily tablet trades needles for a strict morning ritual (empty stomach, plain water, 30-minute wait) that suits rigid-morning people and quietly fails chaotic ones. Daily injections split the difference nobody asked for, which is why liraglutide's case is now mostly price.

Be honest about your life rather than aspirational: the medication only works in the weeks you take it correctly, and adherence beats potency over a two-year horizon.

Established cardiovascular disease tilts toward semaglutide, which carries outcome evidence (a 20% relative reduction in major cardiac events in SELECT). Obstructive sleep apnea tilts toward tirzepatide's dedicated indication. Personal or family MTC/MEN2 history excludes the class; prior pancreatitis triggers the consider-other-therapies conversation.

Tolerability history with one molecule says little about another, but a brutal previous titration argues for slower pacing wherever you land. And timing: if a pipeline drug (oral orforglipron, CagriSema) fits your life better, waiting untreated has real costs; starting something now and reassessing later is usually the stronger play.

Switching between GLP-1s is routine prescriber work with established conventions, usually entering the new drug at a low or middle step. Limited response to one molecule predicts little about the next, and the head-to-head guides (Wegovy vs Zepbound, Ozempic vs Mounjaro) cover the specific trades.

What makes any switch smart instead of hopeful is your own record: three months of doses, side effects, appetite behavior, and weight trend. DoseLog keeps that line automatically, and it turns the which-drug question from a forum debate into a documented conversation with your prescriber.